Study of Aripiprazole in the Treatment of Patients With Acute Symptoms of Bipolar Disorder

This study has been completed.
Information provided by:
Otsuka Pharmaceutical Development & Commercialization, Inc. Identifier:
First received: September 27, 2002
Last updated: November 7, 2013
Last verified: September 2007
The purpose of this study is to learn if aripiprazole is effective in the treatment of patients with acute symptoms of Bipolar Disorder.

Condition Intervention Phase
Bipolar I Disorder
Drug: aripiprazole
Phase 3

Study Type: Interventional
Study Design: Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Otsuka Pharmaceutical Development & Commercialization, Inc.:

Study Start Date: June 2002
Study Completion Date: April 2003
Primary Completion Date: April 2003 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Patients with acute symptoms of Bipolar Disorder
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00046384

United States, Arizona
Local Institution
Scottsdale, Arizona, United States
United States, Arkansas
Local Institution
Little Rock, Arkansas, United States
United States, California
Local Institution
Chula Vista, California, United States
Local Institution
Pico Rivera, California, United States
Local Institution
Riverside, California, United States
Local Institution
San Diego, California, United States
United States, District of Columbia
Local Institution
Washington, District of Columbia, United States
United States, Florida
Local Institution
Winter Park, Florida, United States
United States, New York
Local Institution
Staten Island, New York, United States
United States, Oklahoma
Local Institution
Oklahoma City, Oklahoma, United States
United States, Tennessee
Local Institution
Nashville, Tennessee, United States
United States, Virginia
Local Institution
Falls Church, Virginia, United States
United States, Washington
Local Institution
Bellevue, Washington, United States
Local Institution
Mendoza, Argentina
Sponsors and Collaborators
Otsuka Pharmaceutical Development & Commercialization, Inc.
  More Information

Additional Information: Identifier: NCT00046384     History of Changes
Other Study ID Numbers: CN138-077 
Study First Received: September 27, 2002
Last Updated: November 7, 2013
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Antipsychotic Agents
Central Nervous System Agents
Central Nervous System Depressants
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Therapeutic Uses
Tranquilizing Agents processed this record on April 27, 2016